ArticleNanobiomedicine
Addressing Barriers to the Development and Adoption of Rapid Diagnostic Tests in Global Health.
Article in Nanobiomedicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- How long do rapid diagnostic tests remain positive after anti-malarial treatment?Malaria journal · 2018Pooled it
- Individual and population level uncertainty interact to determine the performance of outbreak surveillance systems.PLoS computational biology · 2026Article
- Quality assurance in rapid diagnostic tests for accurate diagnosis of malaria.The Indian journal of medical research · 2026Review
- Health systems readiness for integration of point-of-care digital diagnostic tools for acute febrile illness in Ghana: a mixed-methods study protocol.BMJ public health · 2026Article
- Perceptions of shorter radical cure Plasmodium vivax treatment regimens and their implementation: a qualitative study among stakeholders in Cambodia.Malaria journal · 2025Article
- Comparative Detection and Genetic Characterization of Feline Panleukopenia Virus in Bangladesh.Veterinary medicine and science · 2025Article
- Acceptability and feasibility of glucose-6-phosphate dehydrogenase (G6PD) testing using SD Biosensor by village malaria workers in Cambodia: a qualitative study.BMJ global health · 2025Article
- Strengthening Outbreak Detection in Africa to Achieve the 7-1-7 Global Framework: Challenges and Opportunities.Public health reviews · 2025Review
- Breaking barriers: The potential of nanosystems in antituberculosis therapy.Bioactive materials · 2024Review
- Commercial Opportunity or Addressing Unmet Needs-Loop-Mediated Isothermal Amplification (LAMP) as the Future of Rapid Diagnostic Testing?Diagnostics (Basel, Switzerland) · 2024Article
- New Agents Are Coming, and So Is the Resistance.Antibiotics (Basel, Switzerland) · 2024Review
- Pilot deployment of a community health care worker in distributing and offering the COVID-19 AgRDT in Tanzania.Scientific reports · 2024Article
- Cost-effectiveness analysis of a multiplex lateral flow rapid diagnostic test for acute non-malarial febrile illness in rural Cambodia and Bangladesh.The Lancet regional health. Southeast Asia · 2024Article
- Implementation of Glucose-6-Phosphate Dehydrogenase (G6PD) testing for Plasmodium vivax case management, a mixed method study from Cambodia.PLOS global public health · 2024Article
- A Review of the Current Status of G6PD Deficiency Testing to Guide Radical Cure Treatment for Vivax Malaria.Pathogens (Basel, Switzerland) · 2023Review
- Diagnostic Performance of Dengue NS1 and Antibodies by Serum Concentration Technique.Tropical medicine and infectious disease · 2023Article
- Article
- Evaluating immunochromatographic test kits for diagnosis of acute human leptospirosis: A systematic review.Heliyon · 2022Review
- Generation of Thermally Stable Affinity Pairs for Sensitive, Specific Immunoassays.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Operational characteristics of an antibody detecting point of care test for Taenia solium infections in a community and hospital setting.BMC infectious diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Immunochromatographic rapid diagnostic tests (RDTs) have demonstrated significant potential for use as point-of-care diagnostic tests in resource-limited settings. Most notably, RDTs for malaria have reached an unparalleled level of technological maturity and market penetration, and are now considered an important complement to standard microscopic methods of malaria diagnosis. However, the technical development of RDTs for other infectious diseases, and their uptake within the global health community as a core diagnostic modality, has been hindered by a number of extant challenges. These range from technical and biological issues, such as the need for better affinity agents and biomarkers of disease, to social, infrastructural, regulatory and economic barriers, which have all served to slow their adoption and diminish their impact. In order for the immunochromatographic RDT format to be successfully adapted to other disease targets, to see widespread distribution, and to improve clinical outcomes for patients on a global scale, these challenges must be identified and addressed, and the global health community must be engaged in championing the broader use of RDTs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.